Trial Profile
A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals With Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2023 Planned primary completion date changed from 31 Jan 2025 to 29 Nov 2024.
- 20 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2023 Planned End Date changed from 30 Oct 2023 to 2 Jan 2026.